
Research


MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
ResearchResearchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.

Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia
ResearchThere is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?

Fungus Among Us: 5 Fascinating Facts About Mushrooms
ResearchScience just keeps discovering how cool and beneficial mushrooms are, with or without psilocybin.

MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA Trials
ResearchA sexual misconduct scandal, a data scandal, and an elder abuse scandal haunt psychedelics leader MAPS, currently being scrutinized by Health Canada.

New Study Links Psilocybin to Lower Risk of Opioid Addiction
ResearchResearchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.

Mushrooms Have Their Own Language, New Study Suggests
ResearchThe electric pulses could be organized into “trains” that resemble human words, and a vocabulary of “up to 50 words” appears to be present.

How to Enroll in a Psychedelic Clinical Trial in 5 Easy Steps
ResearchInterested in participating in a psychedelic study? Here's an in-depth walk through guide so you can take actionable steps to make it happen.

5 Most Important Psychedelic Clinical Trials in 2022
ResearchHere's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.

Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.